← Back to Clinical Trials
Recruiting NCT07037966

NCT07037966 Advancing Portable Brain Imaging: The NextMRI Project's Role in Revolutionizing Diagnostic MRI

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07037966
Status Recruiting
Phase
Sponsor Instituto de Investigacion Sanitaria La Fe
Condition Multiple Sclerosis
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2025-11-07
Primary Completion 2026-09

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
MRIMRI

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2025-11-07 with a primary completion date of 2026-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Mobile imaging diagnostic devices are extremely valuable for clinical diagnosis both inside and outside healthcare facilities. However, Magnetic Resonance Imaging (MRI)-the gold standard for diagnosing many neurological and musculoskeletal conditions-is not easily portable. Moreover, due to its high cost (in the million-euro range) and limited availability, the average wait time in Europe for an MRI scan is from several weeks to months. The NextMRI project aims to take the technical, industrial, and commercial steps required to deploy portable low-field MRI systems in remote and developing regions, rural areas, sporting events, military or medical camps, and home healthcare settings, improving diagnostic capabilities. The specific goals of the NextMRI project are: 1. Expand current low-field MRI technology to brain imaging. 2. Enhance diagnostic accuracy using machine learning. 3. Improve portability and usability for end users. 4. Reduce production costs for broader affordability. 5. Collect clinical evidence through trials to validate medical performance. 6. Develop a sustainable business model for market commercialization.

Eligibility Criteria

Inclusion Criteria: * Patients with suspected multiple sclerosis Exclusion Criteria: * Any contradictions for high-field MRI

Contact & Investigator

Central Contact

Paula Doria Borrell, PhD

✉ paula_doria@iislafe.es

📞 +34629301756

Frequently Asked Questions

Who can join the NCT07037966 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07037966 currently recruiting?

Yes, NCT07037966 is actively recruiting participants. Contact the research team at paula_doria@iislafe.es for enrollment information.

Where is the NCT07037966 trial being conducted?

This trial is being conducted at Valencia, Spain.

Who is sponsoring the NCT07037966 clinical trial?

NCT07037966 is sponsored by Instituto de Investigacion Sanitaria La Fe. The trial plans to enroll 50 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology